Feedforward miR-181d degradation modulates population variance of methyl-guanine methyl transferase and temozolomide resistance
Cell Reports · 2025
DOI: 10.1016/j.celrep.2025.116516 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2025. Verfasst von Gatikrushna Singh und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, University of Minnesota, Minneapolis, MN 55455, USA. Electronic address: gsingh@umn.edu. Hauptthemen laut MEDLINE: MicroRNAs, Drug Resistance, Neoplasm, Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NINDS NIH HHS, NIH NCI.
Abstract (Originalsprache)
Intratumoral heterogeneity plays a pivotal role in cancer evolution, providing the substrate for adaptation to selective pressures, including chemotherapy treatment. Here, we demonstrate that miR-181d modulates variability in methyl-guanine methyl transferase (MGMT) expression, contributing to this heterogeneity in glioblastoma, the most common form of adult primary brain tumor. Treatment with standard-of-care temozolomide (TMZ) chemotherapy triggers a feedforward loop that accelerates polyribonucleotide nucleotidyltransferase 1 (PNPT1)-dependent miR-181d degradation. This degradation requires the activation of ataxia-telangiectasia and Rad3-related (ATR) kinase. The degradation of miR-181d in glioblastoma cells increases the variance of MGMT expression in the cell population, contributing to acquired TMZ resistance. This resistance is suppressed by exogenously transfected miR-181d. These findings suggest that microRNA regulates intratumoral heterogeneity by modulating the transcriptional variability of key DNA repair enzymes, providing a compelling rationale for miRNA delivery as a platform for glioblastoma therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, University of Minnesota, Minneapolis, MN 55455, USA. Electronic address: gsingh@umn.edu.
- Department of Neurosurgery, University of Minnesota, Minneapolis, MN 55455, USA.
- Department of Veterinary Biomedical Sciences, St. Paul, MN 55108, USA.
- VisiCELL Medical Inc., San Diego, CA 92121, USA.
- Department of Pediatrics, Stanford University, Stanford, CA 94304, USA.
- Department of Neurology, Warren Alpert School of Medicine, Rhode Island Hospital, Brown University, Providence, RI 02903, USA.
Förderung
- NINDS NIH HHS
- NIH NCI
Zitieren
APA
Singh, G., Singh, S., Mohapatra, I., Kim, S., Sharma, M., Akers, J., Nguyen, T., Wong, E., Moreno, M. M., Kokkoli, E., Vasudevan, S., Lawler, S. E., El-Deiry, W. S., Gokaslan, Z., & Chen, C. C. (2025). Feedforward miR-181d degradation modulates population variance of methyl-guanine methyl transferase and temozolomide resistance. Cell Reports. https://doi.org/10.1016/j.celrep.2025.116516
Vancouver
Singh G, Singh S, Mohapatra I, Kim S, Sharma M, Akers J, et al. Feedforward miR-181d degradation modulates population variance of methyl-guanine methyl transferase and temozolomide resistance. Cell Reports. 2025. doi:10.1016/j.celrep.2025.116516
BibTeX
@article{Singh2025,
author = {Singh, Gatikrushna and Singh, Shilpi and Mohapatra, Iteeshree and Kim, Stefan and Sharma, Mayur and Akers, Johnny and Nguyen, Thien and Wong, Eric and Moreno, Margot Martinez and Kokkoli, Efrosini and Vasudevan, Shobha and Lawler, Sean E and El-Deiry, Wafik S and Gokaslan, Ziya and Chen, Clark C},
title = {Feedforward miR-181d degradation modulates population variance of methyl-guanine methyl transferase and temozolomide resistance},
journal = {Cell Reports},
year = {2025},
doi = {10.1016/j.celrep.2025.116516}
}
EUVIMED